Reimbursement prices of new, innovative medicines in Germany: a comparison of negotiation and cost-effectiveness analysis
{{output}}
This study aimed to compare reimbursement prices for new, innovative non-orphan drugs in Germany based on price negotiation and cost-effectiveness analysis, using the efficiency frontier (EF) approach and cost-utility analysis (CUA). For the EF, the next effec... ...
